| Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. | |
| | |
MedLine Citation:
|
PMID: 16401674 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: Early statin treatment has beneficial effects on prognosis after acute coronary syndrome. The no-reflow phenomenon determines the prognosis after acute myocardial infarction. We investigated the effects of statin treatment before admission on the development of the no-reflow after infarction. METHODS AND RESULTS: We performed intracoronary myocardial contrast echocardiography in 293 consecutive patients with acute myocardial infarction undergoing successful primary percutaneous coronary intervention. There were no significant differences in the incidence of the no-reflow between the patients with and without hypercholesterolaemia. The 33 patients receiving chronic statin treatment before admission had lower incidence of the no-reflow than those without it (9.1 and 34.6%, P=0.003). They also showed better wall motion, smaller left ventricular dimensions, and better ejection fraction at 4.9+/-2.2 months later. Multivariable logistic regression analysis revealed that statin pre-treatment was a significant predictor of the no-reflow along with anterior wall infarction, ejection fraction on admission, and additional ST-elevation after reperfusion, whereas total cholesterol was not. CONCLUSION: Chronic pre-treatment with statins could preserve the microvascular integrity after acute myocardial infarction independent of lipid lowering, leading to better functional recovery. |
| | |
Authors:
|
Katsuomi Iwakura; Hiroshi Ito; Shigeo Kawano; Atsushi Okamura; Toshiya Kurotobi; Motoo Date; Koichi Inoue; Kenshi Fujii |
Related Documents
:
|
11256844 - Statin therapy: where are we? where do we go next? 8438744 - Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemi... 3698244 - Relationship of angiographically defined coronary artery disease to serum lipoproteins ... 10150224 - Surrogate end-points: the case of trials on coronary atherosclerotic plaque regression. 7963104 - Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase ... 1894864 - Demonstration of myocardial reperfusion injury in humans: results of a pilot study util... |
Publication Detail:
|
Type: Journal Article Date: 2006-01-09 |
Journal Detail:
|
Title: European heart journal Volume: 27 ISSN: 0195-668X ISO Abbreviation: Eur. Heart J. Publication Date: 2006 Mar |
Date Detail:
|
Created Date: 2006-02-20 Completed Date: 2006-07-24 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8006263 Medline TA: Eur Heart J Country: England |
Other Details:
|
Languages: eng Pagination: 534-9 Citation Subset: IM |
Affiliation:
|
Division of Cardiology, Sakurabashi Watanabe Hospital, 2-4-32, Umeda, Kita-ku, Osaka 5300001, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Analysis of Variance Angioplasty, Transluminal, Percutaneous Coronary Coronary Circulation / drug effects*, physiology Echocardiography Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use* Male Middle Aged Myocardial Infarction / physiopathology, therapy*, ultrasonography Myocardial Reperfusion Regression Analysis Stents Stroke Volume Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Association between the metabolic syndrome and parental history of premature cardiovascular disease.
Next Document: Long-term anticoagulant therapy in patients with coronary artery disease.